Genespire raises $52m in Series B to trial paediatric gene therapy
The funds will advance Genespire’s gene therapy for methylmalonic acidemia, a group of rare metabolic disorders, to Phase I/II trials.
The funds will advance Genespire’s gene therapy for methylmalonic acidemia, a group of rare metabolic disorders, to Phase I/II trials.
What's Your Reaction?
